Quoin Pharmaceuticals Advances FDA Approval Process for QRX003
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy QNRX?
Source: Newsfilter
Quoin Pharmaceuticals Ltd's stock surged by 31.13% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The catalyst for this movement is the FDA's indication that a single Phase 3 study may suffice for QRX003's U.S. marketing approval, significantly reducing the original requirement for two studies. This change accelerates Quoin's path to market and enhances its flexibility in clinical trials, particularly for treating Netherton Syndrome. The company aims to complete patient recruitment for its Phase 3 study by the end of 2026 and potentially file for FDA approval in 2027, which would address a critical market need.
This development not only boosts Quoin's prospects for QRX003 but also positions the company favorably in the market, as it could become the first approved treatment for Netherton Syndrome, attracting significant attention from investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.430
Low
70.00
Averages
70.00
High
70.00
Current: 6.430
Low
70.00
Averages
70.00
High
70.00
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quoin Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Beat: Quoin Pharmaceuticals reported a Q1 GAAP EPS of -$1.77, beating expectations by $0.25, indicating improvements in cost control and operational efficiency, which may bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Quoin had approximately $14 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027, ensuring continuity in R&D and marketing efforts.
- Optimistic Operational Outlook: The management expressed optimism regarding the current cash position, believing it will sustain operations and continue product development, reflecting confidence in future market opportunities that may attract more investor interest.
- Positive Market Reaction: Following the earnings release, Quoin Pharmaceuticals' stock price is likely to experience a positive impact, as investor expectations for its future growth potential increase, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Quoin Pharmaceuticals Provides Clinical Update on QRX009 Development
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for the rare skin disease Pachyonychia Congenita in Q3 2026, led by Professor Edel O'Toole from Queen Mary University of London, addressing the lack of approved therapies and potentially enhancing the company's market position in dermatology.
- IND Application Plans: The firm expects to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, along with an additional indication, demonstrating proactive progress in clinical development that may pave the way for future market access.
- Multiple Indication Research: In addition to Pachyonychia Congenita, Quoin plans to initiate clinical studies for Gorlin Syndrome and Tuberous Sclerosis Complex later in 2026, further enriching its product pipeline and strengthening its competitive edge in the rare disease sector.
- Market Performance Analysis: QNRX shares have traded between $5.20 and $41.80 over the past year, closing at $5.45 with a slight decline of 0.18% on the last trading day, yet showing a 9.16% increase in after-hours trading to $5.95, indicating positive market sentiment towards its clinical advancements.
See More
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for Pachyonychia Congenita in Q3 2026, led by renowned Professor Edel O'Toole, which is expected to significantly improve clinical outcomes for patients and address a critical unmet need in the market.
- Exploration of Multiple Indications: In addition to Pachyonychia Congenita, Quoin is also planning to launch studies for Gorlin Syndrome and Tuberous Sclerosis Complex later this year, which will further expand the indications for its product and enhance its competitive position in the market.
- Regulatory Application Progress: The company is on track to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, which, if successful, could open new market opportunities and allow for active testing across multiple indications.
- Strategic Partnerships: Quoin has established relationships with key advocacy foundations such as The PC Project and The Gorlin Syndrome Alliance, which not only enhances its influence in relevant fields but also provides support and resources for future clinical studies.
See More
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for Pachyonychia Congenita in Q3 2026, led by Professor Edel O'Toole from Queen Mary University of London, which is expected to improve clinical outcomes for patients and fill a significant market gap.
- Multiple Indication Exploration: In addition to Pachyonychia Congenita, Quoin is also planning to start studies for Gorlin Syndrome and Tuberous Sclerosis Complex later this year, demonstrating the company's broad strategy in the rare disease sector aimed at enhancing its market competitiveness.
- Regulatory Application Progress: The company is on track to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, potentially allowing active testing in four different indications by the end of 2026, thereby strengthening its market outlook.
- Strategic Partnerships: Quoin has established relationships with key advocacy organizations such as The PC Project and The Gorlin Syndrome Alliance, which will enable the company to better advance its clinical studies and enhance brand influence, supporting its long-term growth in the rare disease market.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Quoin Pharmaceuticals reported a Q4 GAAP EPS of -$1.74, beating expectations by $2.28, indicating an improvement in financial performance despite still being in a loss position.
- Strong Cash Reserves: As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, providing a solid financial cushion for future operations.
- Operational Funding Outlook: The company believes its year-end cash position will sustain operations into 2027, reflecting a prudent approach to cash management that supports long-term growth.
- Increased Market Attention: Following the earnings release, Quoin Pharmaceuticals has garnered heightened market interest, with investors showing greater curiosity about its future profitability and cash flow management.
See More
Quoin Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Beat: Quoin Pharmaceuticals reported a Q1 GAAP EPS of -$1.77, beating expectations by $0.25, indicating improvements in cost control and operational efficiency, which may bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Quoin had approximately $14 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027, ensuring continuity in R&D and marketing efforts.
- Optimistic Operational Outlook: The management expressed optimism regarding the current cash position, believing it will sustain operations and continue product development, reflecting confidence in future market opportunities that may attract more investor interest.
- Positive Market Reaction: Following the earnings release, Quoin Pharmaceuticals' stock price is likely to experience a positive impact, as investor expectations for its future growth potential increase, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Quoin Pharmaceuticals Provides Clinical Update on QRX009 Development
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for the rare skin disease Pachyonychia Congenita in Q3 2026, led by Professor Edel O'Toole from Queen Mary University of London, addressing the lack of approved therapies and potentially enhancing the company's market position in dermatology.
- IND Application Plans: The firm expects to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, along with an additional indication, demonstrating proactive progress in clinical development that may pave the way for future market access.
- Multiple Indication Research: In addition to Pachyonychia Congenita, Quoin plans to initiate clinical studies for Gorlin Syndrome and Tuberous Sclerosis Complex later in 2026, further enriching its product pipeline and strengthening its competitive edge in the rare disease sector.
- Market Performance Analysis: QNRX shares have traded between $5.20 and $41.80 over the past year, closing at $5.45 with a slight decline of 0.18% on the last trading day, yet showing a 9.16% increase in after-hours trading to $5.95, indicating positive market sentiment towards its clinical advancements.
See More
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for Pachyonychia Congenita in Q3 2026, led by renowned Professor Edel O'Toole, which is expected to significantly improve clinical outcomes for patients and address a critical unmet need in the market.
- Exploration of Multiple Indications: In addition to Pachyonychia Congenita, Quoin is also planning to launch studies for Gorlin Syndrome and Tuberous Sclerosis Complex later this year, which will further expand the indications for its product and enhance its competitive position in the market.
- Regulatory Application Progress: The company is on track to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, which, if successful, could open new market opportunities and allow for active testing across multiple indications.
- Strategic Partnerships: Quoin has established relationships with key advocacy foundations such as The PC Project and The Gorlin Syndrome Alliance, which not only enhances its influence in relevant fields but also provides support and resources for future clinical studies.
See More
Quoin Pharmaceuticals Initiates Multiple Clinical Studies for QRX009
- Clinical Study Launch: Quoin Pharmaceuticals plans to initiate a clinical study for Pachyonychia Congenita in Q3 2026, led by Professor Edel O'Toole from Queen Mary University of London, which is expected to improve clinical outcomes for patients and fill a significant market gap.
- Multiple Indication Exploration: In addition to Pachyonychia Congenita, Quoin is also planning to start studies for Gorlin Syndrome and Tuberous Sclerosis Complex later this year, demonstrating the company's broad strategy in the rare disease sector aimed at enhancing its market competitiveness.
- Regulatory Application Progress: The company is on track to submit an Investigational New Drug Application (IND) for QRX009 to the FDA in Q3 2026, potentially allowing active testing in four different indications by the end of 2026, thereby strengthening its market outlook.
- Strategic Partnerships: Quoin has established relationships with key advocacy organizations such as The PC Project and The Gorlin Syndrome Alliance, which will enable the company to better advance its clinical studies and enhance brand influence, supporting its long-term growth in the rare disease market.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Quoin Pharmaceuticals reported a Q4 GAAP EPS of -$1.74, beating expectations by $2.28, indicating an improvement in financial performance despite still being in a loss position.
- Strong Cash Reserves: As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, providing a solid financial cushion for future operations.
- Operational Funding Outlook: The company believes its year-end cash position will sustain operations into 2027, reflecting a prudent approach to cash management that supports long-term growth.
- Increased Market Attention: Following the earnings release, Quoin Pharmaceuticals has garnered heightened market interest, with investors showing greater curiosity about its future profitability and cash flow management.
See More
